← FDA DRUG APPROVALS

FDA ANDA · ANDA219115

DEXLANSOPRAZOLE

Sponsor: ALEMBIC

APPLICATION
ANDA219115
TYPE
ANDA
ORIGINAL APPROVAL
2025-11-12
LATEST ACTION
2025-11-12
ROUTE
ORAL
DOSAGE FORM
CAPSULE, DELAYED RELEASE
MARKETING STATUS
Prescription

Products

DEXLANSOPRAZOLEPrescription
DEXLANSOPRAZOLE 30MG · CAPSULE, DELAYED RELEASE · ORAL
DEXLANSOPRAZOLEPrescription
DEXLANSOPRAZOLE 60MG · CAPSULE, DELAYED RELEASE · ORAL

Approval history

2025-11-12UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →